RCC adjuvant pembroluzimab benefit including ECOG and sex - Evidencio
RCC adjuvant pembroluzimab benefit including ECOG and sex

This tool displays the possible survival benefit that can be achieved with adjuvant pembroluzimab treatment after surgical intervention for renal cell carcinoma (RCC). The calculation incorporates the average survival rate per year of any cause in The Netherlands, the cancer-specific survival based on the Leibovich score (2008 version) and the hazard ratio for adjuvant pembroluzimab therapy from the KEYNOTE-564 study.

Research authors: Olof Sigling, Adriaan D. Bins
Version: 1.0
  • Public
  • Oncology
  • {{ modelType }}
  • Details
  • Save input
  • Load input
Display
Units

Calculate the result

Set more parameters to perform the calculation
Calculating......
Calculation error. Please check the algorithm..

Conditional information

{{ file.classification }}
PRO
Note
Notes are only visible in the result download and will not be saved by Evidencio

This algorithm is provided for educational, training and information purposes. It must not be used to support medical decision making, or to provide medical or diagnostic services. Read our full Disclaimer.

Underlying algorithms Part of
Comments
Comment
Please enter a comment
Comments are visible to anyone

Algorithm feedback

No feedback yet 1 Comment {{ model.comments.length }} Comments
On {{ comment.created_at }} {{ comment.user.username }} a no longer registered author wrote:
{{ comment.content }}
Evidencio v3.35 © 2015 - 2025 Evidencio. All Rights Reserved